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Chronic obstructive lung disease is characterized by persistent abnormalities in epithelial and immune cell 
function that are driven, at least in part, by infection. Analysis of parainfluenza virus infection in mice revealed 
an unexpected role for innate immune cells in IL-13–dependent chronic lung disease, but the upstream driver 
for the immune axis in this model and in humans with similar disease was undefined. We demonstrate here 
that lung levels of IL-33 are selectively increased in postviral mice with chronic obstructive lung disease and 
in humans with very severe chronic obstructive pulmonary disease (COPD). In the mouse model, IL-33/IL-33 
receptor signaling was required for Il13 and mucin gene expression, and Il33 gene expression was localized 
to a virus-induced subset of airway serous cells and a constitutive subset of alveolar type 2 cells that are both 
linked conventionally to progenitor function. In humans with COPD, IL33 gene expression was also associated 
with IL13 and mucin gene expression, and IL33 induction was traceable to a subset of airway basal cells with 
increased capacities for pluripotency and ATP-regulated release of IL-33. Together, these findings provide a 
paradigm for the role of the innate immune system in chronic disease based on the influence of long-term 
epithelial progenitor cells programmed for excess IL-33 production.
Introduction
It is widely believed that the innate immune system mediates 
the acute response to an infectious agent, but recent work shows 
that this response can also translate acute infection into chronic 
inflammatory disease. This paradigm may apply particularly to 
the chronic airway disease found in chronic obstructive pulmo-
nary disease (COPD) (1). In this case, bacterial infection of the 
lower airways is often associated with COPD exacerbation and 
progression (2), but more sensitive PCR-based technology detects 
respiratory viruses in the airway with high frequency as well (3–7). 
Moreover, viral challenge shows that viral infection alone is suffi-
cient to induce COPD exacerbation and to lead to secondary bac-
terial infection with exacerbation (8, 9). Despite these associations, 
a primary cause-and-effect relationship between viral infection 
and the pathogenesis of COPD remains to be fully established. In 
that regard, the relatively transient nature of most respiratory viral 
infections and the relatively permanent nature of chronic inflam-
matory lung disease remain difficult to reconcile. This discrepancy 
appears even more difficult to resolve for inflammation, due to an 
innate immune response that is conventionally viewed as built for 
short-term, rather than long-term, activation.
To better understand the connections among viral infection, 
immune response, and chronic obstructive lung disease, we devel-
oped a mouse model of these events and a corresponding system 
for analysis of COPD patients, from which whole lung explants are 
available for study. Our initial work on the mouse model showed 
that a single infection with a mouse parainfluenza virus known as 
Sendai virus (SeV) leads to long-term airway inflammation (10). 
Analysis of this model uncovered an innate immune axis involving 
semi-invariant NKT cells and alternatively activated (M2) macro-
phages that resulted in IL-13 expression and consequent airway 
hyperreactivity (monitored by methacholine-induced bronchocon-
striction) and mucus overproduction (signified by mucin MUC5AC 
expression) (11). We also found initial evidence of IL-13 expres-
sion along with M2 monocyte/macrophage accumulation and 
MUC5AC production in the lungs of patients with severe COPD 
(11–13). These results identified an innate immune response to 
translate viral infection into chronic obstructive lung disease, but 
still did not explain how the response could be perpetuated.
To address this issue, we reasoned that persistent upstream events 
might continually drive the innate immune axis we had identified. 
In that regard, studies of other experimental models have revealed 
that the innate immune system can control IL-13 production and 
the associated Th2 response with at least 3 key mediators: TSLP, 
IL-25, and IL-33 (14, 15). Each of these 3 cytokines has been report-
ed to be the product of both parenchymal cells (especially at the 
epithelial or endothelial surface) and various immune cells, and 
each has been shown to be necessary for the development of Th2 
inflammation and airway hyperreactivity in experimental models 
of asthma using allergen challenge (16–21). Considerably less is 
known about these cytokines during the innate immune response 
to respiratory viral infection and any associated chronic lung dis-
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ease. Initial work showed that IL-33 receptor (also known as ST2) 
signaling promoted the Th2 response to respiratory syncytial 
virus (RSV) in RSV-G–primed mice (22), but implications for host 
defense or postviral disease are difficult to discern, since the replica-
tion of a human-specific pathogen such as RSV is limited in mice, 
and any effects on airway inflammation and dysfunction are short-
lived (23). A more recent report showed that IL-33 production from 
lung macrophages was required for airway hyperreactivity after 
infection with influenza A virus (IAV) (24). However, similar to the 
RSV model, this study also concentrated on the early response to 
virus, in this case at only 1 day after infection. This outcome may 
not fit with the full spectrum of clinical experience in humans, in 
which inflammatory airway disease might last for weeks and might 
further progress for many years. Moreover, there is little extension 
of these findings in mice to humans. There are preliminary reports 
of increased TSLP in COPD (25) and TSLP, IL-25, and IL-33 in asth-
ma (26–29), but the mechanism for increased expression remains 
uncertain, particularly as it might relate to viral infection. More-
over, there is little information on the effect of these pathways on 
airway mucus production, despite the primary role of this endpoint 
in the morbidity and mortality of obstructive lung disease (30–33).
In the present study, we examined the potential role of TSLP, 
IL-25, and IL-33 in the postviral mouse model and in patients with 
very severe COPD. In both systems, we found that IL-33 was the 
Figure 1
Selective increase in Il33 gene expression in a postviral mouse model of chronic lung disease. (A) Gene expression microarray analysis of mRNA 
from lungs of mice at dpi 49 with SeV (1 × 105 pfu) or SeV-UV. The plot depicts quantile-normalized log2-transformed gene expression values. 
Each symbol represents the expression value for an individual gene. The 20 genes with the greatest relative change, additional relevant genes, 
and those encoding ILs and IL receptors are annotated. Diagonal lines represent line of equality (solid line) and 2-fold expression difference 
(dashed line). Significant differences for SeV versus SeV-UV values (determined as described in Methods) are indicated by colored symbols for 
annotated genes. (B) Expression levels of Il33, Il25, and Tslp mRNA in whole lung tissues from mice with SeV or SeV-UV at dpi 49. (C) Levels of 
IL-33, determined by ELISA, using lung lysates from dpi 49. (D) Levels of Il33, Il13, Muc5ac, and Chi3l3 mRNA at the indicated dpi. (B–D) Values 
represent mean ± SEM (n = 5–7 per condition). *P < 0.05 versus corresponding SeV-UV.
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primary candidate for regulating events upstream to IL-13 produc-
tion. Moreover, IL-33 production localized to types of lung epithe-
lial cells linked to progenitor function in both mice and humans 
(34–36). Indeed, tools for basal cell isolation allowed us to define 
a subset of this population as a potentially renewable source of 
excess IL-33 in COPD. Together, the findings help to reconcile the 
acute and transient nature of the antiviral response of the innate 
immune system, including a new epithelial progenitor cell com-
ponent, with the persistent and sometimes-progressive nature of 
chronic obstructive lung disease.
Results
Increased IL-33 in the mouse model. We analyzed whole genome expres-
sion in lungs from mice inoculated with SeV versus UV-inactivated 
SeV (SeV-UV) and obtained the expected increase in expression of 
genes for mucus production (e.g., Clca3 and Muc5ac) and M2 differ-
entiation (e.g., Alox12e, Arg1, Chit3l3/4, Mmp12, and Retnla) at 49 days 
postinoculation (dpi 49) (Figure 1A and Supplemental Table 1; sup-
plemental material available online with this article; doi:10.1172/
JCI65570DS1). In addition, we found that Il33 gene expression was 
the most upregulated of all IL-encoding genes represented on the 
microarray (Figure 1A and Supplemental Table 1). In contrast, there 
was no significant upregulation of either Il25 or Tslp mRNA level 
at SeV dpi 49. Selective induction of Il33 mRNA was confirmed by 
specific real-time PCR assay of lung mRNA from mice at SeV dpi 
49 compared with mice inoculated with SeV-UV or PBS (Figure 1B 
and data not shown). Moreover, postviral induction of Il33 mRNA 
was accompanied by a corresponding increase in the level of IL-33 
protein in the lung at SeV dpi 49 (Figure 1C). In contrast to the pat-
tern for induction of IL-33, the level of Il25 mRNA was again not 
significantly different, while the level of Tslp mRNA was significantly 
decreased, at SeV dpi 49 (Figure 1B). The time course for Il33 gene 
expression developed in concert with Il13 gene expression, with an 
early increase at SeV dpi 3 and a later increase at dpi 21 that became 
maximal at dpi 49 (Figure 1D). This late increase in Il33 and Il13 gene 
expression corresponded to increases in IL-13 target gene expression, 
including Muc5ac (representative of mucus production) and Chi3l3 
(representative of M2 differentiation) (Figure 1D). This time course 
of gene expression was not found for Il25 or Tslp (Supplemental Fig-
ure 1). Together, these findings suggested linkage between IL-33 
expression and IL-13–dependent lung disease after viral infection.
Requirement for IL-33 in the mouse model. We next used 3 approach-
es to determine whether IL-33/IL-33 receptor signaling is required 
for IL-13 production and consequent chronic lung disease in the 
postviral mouse model. In the first approach, we blocked signal-
ing with a mAb directed against IL-1 receptor–like 1 (IL1RL1), the 
ligand-binding component of the heterodimeric IL-33 receptor. 
We observed a marked decrease in the levels of IL-13+ immune 
cells and MUC5AC+PAS+ mucous cells in the lung at SeV dpi 49 
in mice treated with anti-IL1RL1 mAb compared with untreated 
or control IgG1 mAb–treated mice (Figure 2A). These inhibitory 
effects translated into a corresponding decrease in induction of 
Il13 and Muc5ac gene expression as well as MUC5AC+ mucous cells 
at SeV dpi 49 (Figure 2, B and C). In addition, we also found signif-
icant decreases in the levels of Arg1 and Chi3l3 mRNA in the lung 
at SeV dpi 49 in mice treated with anti-IL1RL1 mAb compared 
with control mice (Figure 2D). These results were consistent with a 
decrease in M2 differentiation during postviral disease. Treatment 
with anti-IL1RL1 mAb was begun on SeV dpi 12, so the effect can-
not be attributed to an action on the acute inflammation and/or 
viral replication found after SeV inoculation, which subside by 
this time (11). In contrast to the decrease in IL-13 production, we 
found no significant changes in Il33 or Il1rl1 mRNA levels during 
anti–IL-33 mAb treatment (Figure 2E). We also observed no gross 
difference in the degree of immune cell infiltration in anti-IL1RL1 
mAb–treated mice, similar to previous results obtained with block-
ade of IL-13/IL-13 receptor signaling (11).
In the second approach, we examined the effect of interrupting 
IL-33/IL-33 receptor signaling using Il1rl1–/– mice. We detected no 
difference in acute illness (as assessed by weight loss, viral level, and 
tissue inflammatory response) between Il1rl1–/– and WT mice after 
SeV inoculation (Figure 3, A–C). However, we again observed sig-
nificant blockade of the expected increases in mucus production, 
IL-13 and MUC5AC immunostaining, and Il13, Muc5ac, and Arg1 
mRNA at SeV dpi 49 in Il1rl1–/– versus WT mice (Figure 3, D–F). 
The Il1rl1–/– mice also afforded an opportunity to determine the 
effect of IL-33/IL-33 receptor signaling on airway hyperreactivity 
after viral infection, since we found alterations in reactivity even 
with control antibody treatment (data not shown). In any case, 
we observed attenuation of postviral increases in absolute values 
for lung resistance at baseline and after methacholine challenge, 
but no significant effect on fold change in baseline resistance after 
methacholine challenge in Il1rl1–/– mice (Figure 3, G and H). These 
results suggest that IL-33/IL-33 receptor signaling to IL-13 produc-
tion does not fully control airway hyperreactivity and that addi-
tional factors may influence this response after viral infection. The 
findings highlight again the relatively potent control of the IL-33–
to–IL-13 axis over airway mucus production after viral infection.
In the third approach, we determined the effect of IL-33 deficiency 
on postviral response using homozygous IL-33 gene trap (Il33Gt/Gt) 
mice, which were engineered with a LacZ reporter to disrupt the 
IL-33 allele (37). In this case, we again found no difference in acute 
illness in Il33Gt/Gt versus WT mice (Figure 4, A–C), but observed sig-
nificant blockade of the expected development of chronic disease, 
signified by IL-13 and mucus production and M2 differentiation 
(Figure 4, D–F). Together with our previous work (11, 12), these 3 
approaches (anti-IL1RL1 mAb, IL1RL1 deficiency, and IL-33 defi-
ciency) served to demonstrate a specific role for IL-33/IL-33 recep-
tor signaling in driving lung IL-13 and mucus production in the 
postviral mouse model of chronic obstructive lung disease.
Consistent with a role for IL-33 production in IL-13–dependent 
disease after viral infection, we found that delivery of IL-33 to 
the mouse airway was also sufficient to cause IL-13 production 
and consequent mucus overproduction (Supplemental Figure 2). 
Administration of IL-25 also caused induction of Il13 and Muc5ac 
gene expression, but blockade of IL-25/IL-25 receptor signaling 
(accomplished using Il25–/– and Il17rb–/– mice as well as by anti–
IL-25 and anti-IL17RB mAb administration) had no significant 
effect on airway inflammation, mucus overproduction, or Il13 
and Muc5ac gene induction at SeV dpi 49 (Supplemental Figure 
2). These results, together with the lack of induction of Il25 gene 
expression in the postviral lung (Figure 1, A and B), indicate that 
IL-25/IL-25 receptor signaling does not contribute significantly to 
IL-13 and mucus production in the postviral mouse model. These 
results contrast with the reported role of IL-25 in driving IL-13 
production in ovalbumin and/or Aspergillus oryzae sensitization-
challenge models of allergic airway disease (17, 38).
IL-33–expressing epithelial cells in the mouse model. We also used 3 
approaches to determine the cellular site for increased IL-33 expres-
sion in the postviral mouse model. In the first approach, FACS-based 
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Figure 2
Effect of IL1RL1 blockade in the postviral mouse model. Mice were inoculated with SeV-UV or SeV, then treated as indicated with anti-IL1RL1 
mAb or control IgG1 mAb (IgG) on dpi 12–49, and examined at dpi 49. (A) Representative photomicrographs of mouse lung sections for IL-13 and 
MUC5AC immunostaining and PAS staining. Scale bars: 200 μm. (B) Lung levels of Il13, Clca3, and Muc5ac mRNA. (C) Levels of MUC5AC+ 
airway epithelial cells. (D). Lung levels of Arg1 and Chi3l3 mRNA. (E) Lung levels of Il33 and Il1rl1 mRNA. (B–E) Values represent mean ± SEM 
(n = 7 per group, representative of 3 experiments). *P < 0.05 versus untreated SeV.
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analysis of lung cell populations was used to demonstrate that the 
levels of Il33 mRNA were increased to the greatest extent in CD45– 
lung cells from mice at SeV dpi 49, whether Il33 level was compared 
across all cell populations (CD45–, CD45+, and CD45+F4/80+) or 
within each individual cell population (Figure 5A and Supplemental 
Figure 3). The levels of Il33 mRNA copies were 600- to 100-fold high-
er in the CD45– cell population compared with CD45+ hematopoi-
etic cells, including CD45+F4/80+ lung macrophages, at SeV dpi 49. 
Within the CD45– population, Il33 mRNA was found primarily in 
cells expressing EpCAM (also known as CD326), consistent with an 
epithelial (and perhaps progenitor/stem) cell origin (Supplemental 
Figure 3 and refs. 39, 40). We also detected an increase in the levels of 
Il33 mRNA in CD45+ cells, including CD45+F4/80+ macrophages, at 
SeV dpi 1 and 3 as well as IAV dpi 1; however, the levels of Il33 mRNA 
were still at least 40-fold higher in CD45– cells, even at these early 
times after infection (Supplemental Figure 3).
In the second approach, we further localized the site for induc-
tion of IL-33 expression using in situ hybridization for Il33 
mRNA. In this case, we again found predominant induction of 
Il33 gene expression in epithelial cells at SeV dpi 49 (Figure 5B). 
The most abundant Il33 mRNA signal was found in airway epi-
thelial cells with morphology typical of serous cells (also known 
as Clara cells). A trace signal was also detected in cells with alve-
olar type 2 cell morphology and was present with and without 
SeV infection. In all cases, the Il33 mRNA signal was cytosolic, as 
expected for mRNA localization.
Figure 3
Effect of IL1RL1 deficiency in the postviral mouse model. Il1rl1–/– and WT mice were inoculated with SeV or SeV-UV. (A) Body weight. (B) Lung 
levels of SeV RNA at dpi 5. (C) Representative photomicrographs showing H&E staining of lung sections at dpi 5. (D) Representative photomi-
crographs showing PAS staining of lung sections at dpi 49. (E) Representative photomicrographs showing IL-13 and MUC5AC immunostaining 
of lung sections at dpi 49. (F) Lung levels of Il13, Muc5ac, Arg1, and Il33 mRNA (n = 5–7 per group). *P < 0.05 versus corresponding WT. 
(G and H) Airway reactivity to inhaled methacholine (MCh) at SeV dpi 49 (n = 15–21 mice per group). (G) Total lung resistance (RL) and fold change 
from baseline were not significantly different by 2- and 3-way ANOVA. (H) Differences for lung resistance at baseline and after methacholine 
(1.25 mg/ml). Scale bars: 200 μm.
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In the third approach, we used heterozygous IL-33 gene trap 
(Il33Wt/Gt) mice, which express the LacZ reporter cassette under 
the endogenous Il33 gene promoter (37) and manifested acute 
and chronic responses to SeV infection similar to those of WT 
mice, including development of mucus production and IL-13 and 
MUC5AC immunostaining (Figure 5C). Il33Wt/Gt mice also showed 
induction of Il33 gene expression (signified by β-gal reporter 
expression) in a subset of cells with location and morphology typi-
cal of airway serous cells at SeV dpi 49, and these cells costained 
with serous cell markers secretoglobin 1a1 (SCGB1A1) and espe-
cially SCGB3A1 (Figure 5D). SCGB1A1 staining was also present 
at baseline conditions (SeV-UV dpi 49), but SCGB3A1 staining was 
more pronounced at SeV dpi 49. These results were consistent with 
whole genome expression microarray of lung tissue that showed 
increased mRNA for airway serous cell genes (e.g., Scgb3a1 and 
Cyp7b1) at SeV dpi 49 compared with SeV-UV infection (Figure 1A 
and Supplemental Table 1). We also detected IL-33/β-gal expres-
sion in a subset of cells with location and morphology typical of 
alveolar type 2 cells that costained with the alveolar type 2 cell 
marker surfactant protein C (SFTPC), but these signals were also 
found at baseline, as noted previously (37).
We also detected KRT5+ basal cells in the distal airway and in the 
parenchyma (Figure 5E). This cell population is normally restricted 
to the trachea (36, 41), but is detectable after IAV infection in the 
same location as that after SeV infection (42). This result was also 
consistent with whole genome expression of lung tissue at SeV dpi 49 
that showed significant increases in mRNA for basal cell genes (e.g., 
Krt5, Krt14, Krt15, Krt17, Aq3, Trp63, and Ngfr) (Figure 1A and Supple-
mental Table 1). However, IL-33/β-gal expression was not detected in 
KRT5+ basal cells, MUC5AC+ mucous cells, α-tubulin+ ciliated cells, 
or F4/80+ monocytes/macrophages (Figure 5E and Supplemental 
Figure 4). IL-33/β-gal expression was no longer detectable in WT 
Figure 4
Effect of IL-33 deficiency in 
the postviral mouse model. 
Il33Gt/Gt and WT mice were 
inoculated with SeV or 
SeV-UV. (A) Body weight. 
(B) Lung levels of SeV RNA 
at dpi 5. (C) Representative 
photomicrographs showing 
H&E staining of lung sec-
tions at dpi 5. (D) Repre-
sentative photomicrographs 
showing PAS staining of 
lung sections at dpi 49. (E) 
Representative photomicro-
graphs showing IL-13 and 
MUC5AC immunostaining 
of lung sections at dpi 49. 
(F) Lung levels of Il13, 
Muc5ac, Arg1, and Il1rl1 
mRNA (n = 5–7 per group). 
*P < 0.05 versus corre-
sponding WT. Scale bars: 
200 μm.
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mice (Supplemental Figure 4), thereby excluding the nonspecific 
staining found for anti-mouse IL-33 antibodies (37). The present 
approach also offers the advantage of detecting only IL-33 produc-
tion, not IL-33 bound to its receptor on the target cell. Together, the 
concerted approaches for IL-33 localization (i.e., PCR assay of FACS-
purified cells, in situ hybridization, and IL-33 reporter mice) indi-
cated that IL-33 expression in postviral mice with chronic obstruc-
tive lung disease is traceable to a newly induced subset of airway 
serous cells marked especially by SCGB3A1 expression as well as a 
constitutive subset of alveolar type 2 cells marked by SFTPC expres-
sion. Thus, IL-33 expression marks an airway serous cell population 
linked previously to repair, renewal, and remodeling in the distal air-
way epithelium (34, 35, 43, 44) and an alveolar type 2 cell population 
responsible for the same progenitor functions in the alveolar com-
partment (45, 46). The findings suggested that an IL-33–expressing 
progenitor cell population might be a feature of chronic obstructive 
lung disease, so we pursued this possibility in humans.
IL-33–expressing basal cells in COPD in vivo. To translate our findings 
from the mouse model to humans, we used whole lung explants 
from recipients undergoing lung transplantation for very severe 
Figure 5
Localization of IL-33 expression to subsets of lung epithelial cells in the postviral mouse model. (A) Levels of Il33 mRNA from lung tissue prepara-
tion (Tissue Prep), lung cell preparation before FACS (Cell Prep), and the indicated cell populations purified by FACS from lungs obtained at dpi 49. 
Values are representative of 3 experiments. (B) Representative photomicrographs showing in situ hybridization for Il33 mRNA at dpi 49. (C) 
Representative photomicrographs showing PAS staining and IL-13 and MUC5AC immunostaining in Il33Wt/Gt lung sections at dpi 49. (D) Repre-
sentative photomicrographs showing IL-33 immunostaining (detected with anti–β-gal antibody) and indicated cell type–specific costaining and 
DAPI counterstaining in Il33Wt/Gt lung sections at dpi 49. (E) Representative photomicrographs for additional immunostaining using conditions in D. 
Boxed regions in B–E are shown at higher magnification below (enlarged ×2). Scale bars: 200 μm (B and C); 100 μm (D and E).
Downloaded on October 19, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/65570
research article
3974 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 9   September 2013
(GOLD Stage IV) COPD (Supplemental Table 2), compared with 
lungs from non-COPD donors, to assess expression of TSLP, IL-25, 
and IL-33. We found significantly increased IL33 mRNA levels in 
lung samples from COPD versus non-COPD subjects (Figure 6A). 
To better address the relationship of increased IL-33 expression to 
airway disease (particularly mucus production), we also examined 
lung samples directed to airways based on CT imaging (47). In these 
airway-rich sections, we again found a significant increase in IL33 
mRNA in COPD versus non-COPD subjects as well as increased 
levels of IL13, IL13RA1, and MUC5AC mRNA (Supplemental Fig-
ure 5), consistent with our previous observations in smaller groups 
of subjects (11, 13). Moreover, IL33 mRNA levels correlated with 
MUC5AC and IL13RA1 mRNA levels across the group of COPD and 
non-COPD lung samples (Supplemental Figure 5). We did not find 
Figure 6
Selective increase in IL-33–expressing airway epithelial cells in COPD. (A). Levels of IL33, IL25, and TSLP mRNA in non-COPD (n = 7) and COPD 
(n = 15) lung tissues. (B) Levels of IL-33, determined by ELISA, using non-COPD (n = 16 samples from 9 subjects) versus COPD (n = 17 samples 
from 11 subjects) lung lysates. (C) Levels of IL33 mRNA in lung cells before FACS (Pre-sort Cells) and the indicated cell populations purified 
by FACS from COPD subjects (n = 4) using labeled anti-CD45 and anti-CD14 mAb. (D) Representative photomicrographs of sections of airway 
epithelium immunostained for IL-33 with DAB (brown) reporter and counterstained with tartrazine (yellow). (E) Number of IL-33+ cell nuclei per 
millimeter basement membrane in non-COPD (n = 6) versus COPD (n = 10) lung tissues. (F) Representative photomicrographs of non-COPD 
and COPD airway epithelium sections immunostained for IL-33 with red (Alexa Fluor 594) reporter; costained for MUC5AC, SCGB1A1, or FOXJ1 
with green (Alexa Fluor 488) reporter; and counterstained with DAPI (blue). (A, B, and E) Box represents 25th–75th percentile; line represents 
median; “+” represents mean; whiskers represent range. (C) Bars represent mean ± SEM. P values were derived from unpaired Student’s t test, 
but comparisons of medians were also made using Mann-Whitney U test with similar results. Scale bars: 100 μm.
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a correlation of IL13 with expression of IL33, IL13RA1, or MUC5AC, 
perhaps a reflection of the relatively transient and low-level produc-
tion of cytokines (such as IL-13) versus more stable and higher-level 
expression of trigger, receptor, and responder components (such 
as IL-33, IL-13 receptor, and MUC5AC) of the cytokine signaling 
pathway. Although there was some degree of heterogeneity among 
individual patients, we found no significant difference in either 
IL25 or TSLP mRNA levels in COPD versus non-COPD subjects 
(Figure 6A). The increase in lung IL33 mRNA levels was accompa-
nied by a significant increase in IL-33 protein levels in lung samples 
from COPD versus non-COPD subjects (Figure 6B).
We next traced the cellular source of increased IL-33 production 
in the lungs of COPD subjects. Analysis of FACS-purified lung cell 
populations indicated that the primary source of IL33 mRNA pro-
duction in COPD was CD45– nonhematopoietic cells (Figure 6C 
and Supplemental Figure 6). In concert with this finding, IL-33 
immunostaining was most intense in airway basal cells present 
in regions of epithelial hyperplasia and mucous cell remodeling 
with and without associated bronchial-associated lymphoid tissue 
(BALT) (Figure 6D and Supplemental Figure 6) and was charac-
terized by an increased number of IL-33+ airway epithelial cells in 
samples from COPD versus non-COPD subjects (Figure 6E). These 
findings were consistent with detection of increased IL33 mRNA in 
airway-containing samples from COPD versus non-COPD subjects. 
We found no detectable IL-33 staining in more differentiated air-
way epithelial cells, i.e., MUC5AC+ mucous cells, SCGB1A1+ serous 
cells, or FOXJ1+ ciliated cells, in non-COPD or COPD subjects 
(Figure 6F). We did detect IL-33 immunostaining of endothelial 
cells of the lung microvasculature along with scattered cells in the 
interstitium, which in both cases was again localized to the nucleus.
Figure 7
Localization of IL-33 expression 
to a subset of airway basal cells 
in COPD. (A) Levels of KRT5, 
KRT14, and TRP63 mRNA in 
non-COPD (n = 18) and COPD 
(n = 21) lungs. (B) Representa-
tive photomicrographs of non-
COPD and COPD airway epi-
thelium sections immunostained 
for IL-33; costained for KRT5, 
KRT14, TRP63, or SCGB3A1; 
and counterstained with DAPI. 
Boxed regions are shown at high-
er magnification at right (enlarged 
×4). Scale bars: 100 μm.
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Figure 8
Basal cell capacity for tracheobronchosphere formation and IL-33 release in COPD. (A) Representative photomicrographs of hTECs isolated 
from COPD subjects, cultured in 2D submerged conditions for 5 days, and immunostained for IL-33 and TRP63 and counterstained with DAPI. 
(B) IL-33 levels in cell lysates for non-COPD and COPD subjects (n = 3 per group) as in A. (C and D) Flow cytometric analysis of hTECs cultured 
from COPD and non-COPD subjects (n = 3 per group) and then permeabilized and stained for IL-33, ITGA6, and NGFR along with unstained 
non-COPD control. (C) Representative cytograms. FL1, autofluorescence signal; FSc, forward scatter. Values indicate percent of cells within the 
designated gate. (D) Histograms. (E) Representative photomicrographs showing IL-33 and ITGA6 immunostaining as in A. (F) Representative 
photomicrographs of tracheobronchospheres in 3D culture using phase contrast and fluorescent microscopy for immunostaining for ablumenal/
basal KRT14 and lumenal/apical KRT8. (G) Quantitation of tracheobronchosphere formation for basal cells with and without FACS purification 
from non-COPD (n = 3) and COPD (n = 5) subjects, using sorting and culture conditions as in C and F. (H) Levels of IL-33 released from hTECs 
isolated from a COPD and a non-COPD subject, cultured submerged for 5 days, and then incubated with ATP for the indicated time periods. 
Results are representative of 3–5 subjects. *P < 0.05 versus PBS at 0 h, 2-way ANOVA. Scale bars: 25 μm (A and E); 100 μm (F).
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The increase in IL-33–expressing airway basal cells was accom-
panied by significant increases in expression of conventional basal 
cell genes (i.e., KRT5, KRT14, and TRP63) in the lungs of COPD 
versus non-COPD subjects (Figure 7A). Moreover, IL-33 expres-
sion was localized to a subset of KRT5+, KRT14+, and TRP63+ air-
way basal cells, again particularly prominent in areas of epithelial 
hyperplasia and mucous cell remodeling in COPD (Figure 7B). 
IL-33 did not overlap completely with KRT5, KRT13, or TRP63 
immunostaining, which suggests that IL-33–expressing cells rep-
resent a distinct airway basal cell niche. We did not detect IL-33 
immunostaining in SCGB3A1+ airway serous cells (in contrast to 
the mouse model) or in alveolar or tissue macrophages (Figure 7B 
and data not shown). Based on the role of TRP63 in suppression 
of apoptosis and prolongation of epithelial cell survival (48), simi-
lar to the case for EpCAM (40), our findings again suggested that 
IL-33 expression may mark a progenitor cell population.
IL-33–expressing basal progenitor cells in culture. Given the tools 
available for analysis of lung progenitor cells, we next examined 
whether the IL-33 expression program continues ex vivo in basal 
cells isolated from COPD and non-COPD subjects. We used whole 
lung explants for blunt dissection of airways and then isolation 
and culture of human tracheobronchial epithelial cells (hTECs) 
under submerged conditions. These conditions prevented epithe-
lial cell differentiation and thereby preserved airway basal cells, 
including the IL-33+TRP63+ subset (Figure 8A). We found that, in 
contrast to submerged culture conditions, IL33 mRNA was 150-
fold decreased and IL-33 protein was undetectable with cell dif-
ferentiation in air-liquid interface conditions (data not shown). 
Under submerged culture conditions, we also found that levels of 
IL-33 expression were significantly increased in basal cells from 
COPD versus non-COPD subjects even after 5 days in culture 
(Figure 8B). We then subjected hTECs from submerged cultures to 
intracellular staining for IL-33 along with detection of cell surface 
markers that are selective for airway basal cells (i.e., nerve growth 
factor receptor [NGFR] and integrin α6 [ITGA6]) (36). This strategy 
revealed an association of IL-33 expression with an ITGA6hiNGFRlo 
subpopulation of basal cells in both COPD and non-COPD sub-
jects (Figure 8C), again with increased levels of IL-33 expression in 
COPD versus non-COPD cells (Figure 8D).
Given the conventional role of basal cells as epithelial progenitors 
in human airways (36, 42) as well as the association of IL-33 expres-
sion with typically progenitor cell populations in the mouse model, 
we next checked for progenitor potential in basal cells isolated from 
COPD and non-COPD subjects. We found that IL-33+ basal cells 
placed into an enriched 3D Matrigel culture system were fully capa-
ble of forming structures with fidelity to original airway morphol-
ogy (designated tracheobronchospheres). After culture of these tra-
cheobronchospheres under differentiation-promoting conditions, 
phase-contrast microscopy and video microscopy revealed proper 
ciliary formation and movement (Figure 8F and Supplemental 
Video 1), and immunofluorescence microscopy showed ablumenal 
KRT14 and lumenal KRT8 expression, as expected for differenti-
ated airway structure (36). Moreover, we observed a significantly 
increased efficiency of sphere formation from cultures that were 
enriched for IL-33–expressing (ITGA6hiNGFRlo) cells (Figure 8G). 
Increased sphere formation was also found for cells obtained from 
COPD versus non-COPD subjects (Figure 8G). These results pro-
vide evidence of a progenitor subset of airway basal cells that is 
marked by IL-33 expression and is increased in COPD.
Our results from the postviral mouse model also indicated that 
IL-33 must reach the extracellular space and bind to its receptor for 
the development of lung disease (since disease was blocked using 
anti-IL1RL1 mAb and by loss of IL1RL1). We therefore examined 
the capacity for IL-33 release from basal cells, in light of previous 
observations that extracellular ATP may act as a danger signal to 
trigger IL-33 release by activation of purinergic receptor P2Y2R 
signaling (49). Consistent with this concept, direct administration 
of ATP caused a significant increase in IL-33 release in basal cells 
cultured from both COPD and non-COPD subjects (Figure 8H). 
Under these conditions, IL-33 was detected exclusively in the api-
cal medium and was found to accumulate at increasing levels over 
1–3 days. We found no significant difference in cell morphology or 
LDH release in ATP- versus PBS-treated COPD or non-COPD sub-
jects (Supplemental Figure 7), consistent with a previous report of 
noncytotoxic release of IL-33 (49). These data implicate a regulated 
secretory process by which IL-33 release is directed under condi-
tions of cellular stress. Taken together, these findings indicate that 
a subset of the airway basal cells is programmed for IL-33 expres-
sion and release and that an increase in this cell population can 
thereby serve as a renewable source of increased IL-33, with the pos-
sible downstream consequence of IL-13–dependent lung disease.
Discussion
It has been difficult to understand how an acute infection might 
lead to a chronic inflammatory disease. We gained substantial 
insight into this process with studies of viral infection in mice 
Figure 9
IL-33/IL-13 immune axis in chronic obstructive lung dis-
ease. Respiratory viral infection leads to an increase 
in lung epithelial progenitor cells (airway basal cells in 
humans, and perhaps airway serous cells and alveolar 
type 2 cells in mice) that are programmed for increased 
IL-33 expression. Subsequent epithelial danger signals 
stimulate ATP-regulated release of IL-33 that acts on 
immune cells in the lung, e.g., CD4+ Th2 cells, innate 
lymphoid cells (ILC), and semi-invariant NKT cells 
with interacting monocytes and macrophages (Mono) 
to stimulate IL-13 production and consequent airway 
mucous cell and mucus formation.
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ized airway cell niche. The basis for how such a population might 
develop still needs to be defined, but our present results suggest 
that an epigenetic change in this population, perhaps a result of 
viral reprogramming, might allow for increased abundance of a 
progenitor subset marked by IL-33 expression.
In pursuing this question, it may be useful to recognize that the 
progenitor cell program can be relatively inefficient when assessed 
by tracheobronchosphere formation (e.g., 18 spheres per 3,000 
cells seeded, or approximately 0.6% in samples from COPD sub-
jects), as reported previously (36, 51, 52). However, sphere-forming 
efficiency is likely decreased by several of the present experimental 
conditions, e.g., cellular stress during isolation, cell seeding at low 
density, and lack of additional supplementation with growth fac-
tors and/or fibroblast feeder layers. Further work will be needed to 
determine the precise relationship of progenitor cell function to 
IL-33 expression and whether IL-33 serves as a marker or a driver 
of self renewal and/or mucous cell differentiation. Nonetheless, 
the increase in sphere-forming efficiency in IL-33–enriched popu-
lations in samples from COPD and non-COPD subjects suggests 
at least some degree of linkage between IL33 gene expression and 
progenitor cell function.
The progenitor nature of an IL-33–expressing, ATP-responsive 
cell population could explain the acquired susceptibility to excess 
mucus production typical of airway disease, but this response may 
also provide an advantage to the host. Others previously reported 
a protective role for IL-33 signaling after high-dose intracerebral 
lymphocytic choriomeningitis virus (LCMV) infection, but found 
no change in viral clearance at lower inoculum (53), similar to 
our present results. However, as noted above, it may be useful to 
consider the chronic condition: long-term IL-33 production may 
provide for increased airway mucous cells that may be less sus-
ceptible to viral infection (54) and facilitate the immune response 
(55). Similarly, mucus production may facilitate export of noxious 
materials via cough and/or mucociliary clearance. It is possible 
that these mucous cell benefits are lost if other environmental 
stimuli, such as tobacco smoke or allergen, are introduced in con-
junction with viral infection to drive excessive mucus production. 
This issue will require further studies of viral infection in combi-
nation with other risk factors for chronic obstructive lung disease.
Our present findings also reinforce and expand the unusual 
role of IL-33 as a secreted cytokine despite nuclear expression. In 
the postviral mouse model, extracellular IL-33 acts in a paracrine 
manner by interacting with its cognate receptor to drive IL-13 pro-
duction and consequent M2 differentiation and mucus overpro-
duction. In this case, administration of anti-IL1RL1 or engineered 
deficiency of IL1RL1 blocks these effects (56, 57). In our studies of 
human lung cells, available tools permitted localization of IL-33 
to the nuclei of airway basal cells in vivo and in vitro. This situa-
tion was consistent with the proposal that IL-33 is constitutively 
expressed at a high level in basal cells of other epithelial barriers 
(e.g., skin and genitourinary tract) and can be released with cellular 
stress (37, 49). Whether release of IL-33 for activation of its recep-
tor is regulated by cell turnover or by alarm signals from external 
stimuli likely depends on the stimulation conditions, but at least 
in the mouse model, long-term induction and action of IL-33 
appears to continue without any obvious stimulus for cell death or 
damage. Nonetheless, our results using basal cells indicated that 
further cellular stress and consequent ATP release could stimu-
late even higher levels of IL-13 expression, M2 differentiation, and 
mucus production. These characteristics of IL-33 processing and 
aimed at modeling the initiation, exacerbation, and progression 
of chronic obstructive lung diseases such as COPD. In our mouse 
model of this disease process, we uncovered an innate immune axis 
involving semi-invariant NKT cells and M2 monocytes and macro-
phages that drives IL-13 production and consequent airway mucus 
production and hyperreactivity that are characteristic of chronic 
obstructive lung disease in humans (10–12, 44, 50). We recognized, 
however, that there must be upstream factors that more directly 
link acute viral infection with chronic activation of immune effec-
tor cells. In the present study, we assessed the factors best known to 
regulate IL-13 production, i.e., IL-25, TSLP, and IL-33, and showed 
that IL-33 was a primary influence on the innate immune axis 
that drives IL-13–dependent lung disease. Our present findings 
suggested a primary role for IL-33 in experimental (mouse) and 
clinical (human) forms of chronic lung disease. (a) In the postviral 
mouse model, IL-33 expression was selectively induced relative to 
IL-25 and TSLP, and IL-33/IL-33 receptor signaling was required 
for chronic increases in IL-13 and airway mucus production. (b) 
In this model, IL-33 expression was particularly localized to air-
way serous cells and alveolar type 2 cells, which suggests that a 
progenitor population might account for long-term IL-33 expres-
sion and consequent IL-13–dependent disease. (c) In humans with 
very severe COPD, IL-33 expression was also selectively increased 
in lung tissue and was significantly associated with an IL-13 and 
mucin gene signature, in concert with excess airway mucus pro-
duction. (d) In these subjects as well as in control subjects, IL-33 
expression was particularly localized to nuclei in a subset of airway 
basal cells that were increased in COPD and are also conventionally 
linked to progenitor function. (e) In an ex vivo analysis of this basal 
cell subset, increased nuclear expression of IL-33 was preserved in 
basal cells cultured from COPD subjects and marked a cell popu-
lation with increased pluripotency and ATP-regulated release of 
IL-33. Together, these results suggest a new scheme for an IL-33/
IL-13 immune axis in which an epithelial progenitor cell popula-
tion can store and release IL-33 to drive downstream IL-13 and 
consequent airway mucus production that is typical of COPD and 
perhaps other IL-13–dependent diseases (Figure 9).
An intriguing aspect of our findings is the potential role of an 
inducible progenitor population in the development of chronic 
inflammatory disease. Full development of this concept is limited 
by our present understanding of the progenitor populations in 
lung injury and repair, including the renewal process that occurs 
after viral infection. In other mouse models of this process (with 
and without cell lineage tracking), airway serous cells in the distal 
airway and alveolar type 2 cells in the alveolar space are generally 
regarded as progenitors (34, 35, 45, 46), but whether they can be 
reprogrammed (e.g., by viral infection) to drive chronic disease rep-
resents a new paradigm for pathogenesis. Airway and parenchymal 
basal cells (marked by KRT5 expression) may develop after IAV and 
SeV infection (ref. 42 and the present study), but specific disease-
producing functions of this cell population remain uncertain. For 
example, we did not find IL-33 expression in this basal cell popu-
lation in the postviral mouse model of chronic obstructive lung 
disease. Conversely, it is also generally accepted that airway basal 
cells are linked to progenitor function in human lungs (36, 41); 
here, we confirmed this proposal and established a further con-
nection to regulated IL-33 expression and release in human lung 
disease. Since IL-33 expression did not fully coincide with that of 
other basal cell markers, the IL-33–expressing basal cells (as well 
as the IL-33+ serous cells in mice) appear to represent a special-
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endothelial cells (69), but whether this system is involved in IL-33 
expression in airway epithelial cells or has any role in inflamma-
tory lung disease still needs to be defined.
In summary, we used a mouse model of chronic obstructive lung 
disease to guide our understanding of the immune pathways that 
contribute to similar disease due to COPD in humans. In both the 
mouse model and in COPD subjects, we detected induction of an 
IL-33–expressing epithelial cell population with progenitor char-
acteristics that could account for long-term activation of an innate 
IL-13 immune axis. The consequent accumulation of inflamma-
tory airway mucus is critical to the morbidity and mortality of 
chronic lower respiratory disease (31, 32, 70), which now ranks as 
the third most common cause of death in the United States and 
the fifth worldwide (71, 72). The relationship of the epithelial cell 
IL-33–to–immune cell IL-13 pathway with other risk factors for 
COPD, such as tobacco smoking, still needs to be defined. None-
theless, our results suggest that viral infection is a suitable can-
didate to drive acute exacerbations with long-term consequences 
for progression and consolidation of chronic obstructive lung 
disease. In fact, viral infection appears significantly more potent 
than smoke exposure as a stimulus of airway inflammatory disease 
under experimental conditions (73, 74). This issue will be better 
settled as key immune components, e.g., IL-33 and IL-13, are effec-
tively blocked in patients with chronic lung disease. The present 
findings lay the groundwork for this therapeutic strategy and pro-
vide a rational basis for how acute infectious agents (such as com-
mon respiratory viruses) can reprogram long-term progenitor cells 
(such as airway basal cells) to cause chronic inflammatory disease.
Methods
Mouse generation and treatment. Male mice (6–12 weeks of age) on a C57BL/6 
background were used for all experiments. WT C57BL/6J mice were 
obtained from Jackson Laboratories. Il25–/– mice (75) were provided by A. 
McKenzie (Cambridge, England) and backcrossed to C57BL/6 for a total 
of 10 generations. Il17rb–/– mice on a C57BL/6 background as well as anti-
mouse IL-25 (clone M819) and IL17RB (clone M735) mAbs (76) were pro-
vided by A. Budelsky (Amgen, Seattle, Washington, USA). Il1rl1–/– mice 
(56, 57) were obtained from P. Bryce (Northwestern University, Chicago, 
Illinois, USA). Il33Gt/Gt mice were generated with insertion of a gene trap 
cassette containing the LacZ (bgeo) reporter into intron 1 of the Il33 locus, 
as described previously (37). Anti-mouse IL1RL1 (clone M955) and con-
trol IgG1 (clone 4D2) mAbs were provided by D. Smith (Amgen, Seattle, 
Washington, USA). Mice were inoculated with either SeV (1 × 105 pfu), an 
equivalent amount of SeV-UV, or PBS, as described previously (11). Inocula-
tion with SeV-UV and PBS gave identical results and were therefore treated 
as equivalent control conditions. For mAb blocking experiments, mice 
were injected at weekly intervals beginning at dpi 12 with anti–IL-25 mAb 
(500 μg/wk), anti-IL17RB mAb (500 μg/wk), anti-IL1RL1 mAb (200 μg/wk), 
or an equivalent amount of control Ig given intraperitoneally, as described 
previously (76, 77). For cytokine administration, recombinant mouse IL-25 
and IL-33 (R&D Systems) were reconstituted per the manufacturer’s recom-
mendations, diluted in PBS, and administered intranasally.
Gene expression microarray. Gene expression analysis was performed using 
Illumina Mouse-WG6 v2 BeadChips (Illumina). Total RNA was isolated 
from lung homogenates using the RNEasy kit (Qiagen) and was ampli-
fied and biotinylated using the Illumina TotalPrep Kit (Ambion). Treat-
ment and conditions were randomized across BeadChip slides to avoid 
confounding (78). Hybridization and scanning of BeadChip arrays was 
performed with BeadStudio 3.0 software (Illumina). Microarray normal-
ization and analysis was performed with Bioconductor packages in the 
action would fit with our observations that it was a more robust 
marker of chronic lung disease, even at baseline, compared with its 
downstream readouts.
Our results also help to clarify the cellular target of IL-33 
action. Others have proposed a role for IL-33 derived primarily 
from alveolar macrophages in the development of airway hyper-
reactivity after IAV infection (24). This conclusion was based on 
immunostaining with anti-mouse IL-33 antibody (24), which 
has been problematic, as noted above and in previous reports 
(37). In contrast, our work and that of by others showed that 
IL-33 expression was often localized to nonhematopoietic cells 
(37, 53, 58, 59, and the present study). Indeed, our findings fit 
best with immune cells being a target, rather than a source, of 
IL-33. The precise and quantitative identification of the immune 
cell populations that respond to IL-33 with production of IL-13 
during postviral disease in mice or chronic obstructive lung dis-
ease in humans is still being fully defined. Our initial study of 
this issue pointed to a predominant functional role for NKT 
cells and monocytes/macrophages (11), but we also recognized 
that IL-13–producing innate lymphoid cells were also activated 
in the postviral mouse model (60, 61). A comprehensive analy-
sis of IL-13–producing cells in the mouse model and in human 
subjects — and, ultimately, selective blockade of these popula-
tions — will be required to fully define this issue. It remains pos-
sible that IL-33 has additional effects on airway epithelial (and 
endothelial) cells in the lung, as described previously (62, 63), 
but the functional consequences of this action under healthy or 
disease conditions remain uncertain.
Others have also proposed a role for IL-25 and TSLP in the devel-
opment of chronic obstructive lung disease due to asthma (26, 27), 
and, to a much more limited extent, in COPD (25). We did not 
detect significant differences in lung levels of IL25 or TSLP mRNA 
in our cohort of COPD patients with very severe disease compared 
with non-COPD controls, but we cannot exclude a role for these 
cytokines in controlling IL-13 production or some other aspect 
of lung disease. In fact, we did observe upregulation of IL-25 and 
TSLP expression in the lungs of some subjects with severe COPD, 
but not all. Given the potent action of IL-25 on induction of IL-13 
expression, at least in mice, it is possible that IL-25 (with or with-
out synergy with IL-33) could contribute to overproduction of 
mucus in some individuals. In the case of TSLP, however, we found 
only low levels of expression in COPD and a decrease in expression 
after viral infection in mice. While further studies of TSLP func-
tion need to be done, our present data suggest that the contribu-
tions of TSLP to obstructive lung disease may not derive from its 
direct actions in the lung. TSLP is reported to have potent effects 
in the skin that may lead to allergic asthma (64), but there is no 
connection as yet to nonallergic lung disease.
Similarly, population studies indicate an association of SNPs 
near IL1RL1 on chromosome 2 and IL33 on chromosome 9 with 
the development of asthma (65–67), but to our knowledge, no 
similar associations have been reported for COPD thus far (68). 
Moreover, the present results suggest that environmental agents 
(i.e., viral infection) may alter IL-33 expression, making it likely 
that epigenetic approaches may be more informative than studies 
of gene sequence in identifying a basis for COPD-related differ-
ences in airway epithelial cells. Similarly, we do not yet understand 
the genetic or acquired regulatory events that control IL33 gene 
expression or IL-13 protein processing in progenitor cells. There 
is a report of Notch dependency for IL-33 expression in vascular 
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Biosciences). For hTEC experiments, cells were detached from inserts with 
trypsin/EDTA solution and immunostained using anti-NGFR rabbit Ab 
(Abcam) detected with APC-conjugated anti-rabbit Ab (Santa Cruz) and 
PE-Cy7–conjugated anti-ITGA6 rat Ab (Ebioscience). For IL-33 costaining, 
cells were then fixed with 4% paraformaldehyde, permeabilized with 0.5% 
IGEPAL (Sigma-Aldrich), immunostained with biotinylated anti–IL-33 
mAb (clone Nessy-1, Enzo Life Biosciences) and PE-labeled streptavidin 
(BD Pharmingen), and costained using anti-NGFR rabbit Ab (Abcam) 
detected with APC-conjugated anti-rabbit Ab (Santa Cruz) and PE-Cy7–
conjugated anti-ITGA6 rat Ab (Ebioscience). Flow cytometry results were 
plotted and analyzed using FlowJo software (TreeStar).
In situ hybridization. Tissue sections were pretreated to block nonspecific 
binding and then hybridized overnight with digoxygenin-labeled antisense 
RNA probe for Il33 mRNA, as described previously (94). After stringent 
washing and RNase treatment, Il33 mRNA was detected using an antibody-
linked alkaline phosphatase reaction with BM purple chromophore (Roche 
Diagnostics), and sections were counterstained with nuclear fast red.
Cytokine ELISA. ELISA for human and mouse IL-33 was performed using 
IL-33 Duosets (R&D Systems) according to the manufacturer’s protocol. 
For mouse and human sample preparation, lung tissues were homoge-
nized in T-PER reagent containing HALT protease inhibitors (Pierce), and 
the tissue lysate was diluted (2 μl in 100 μl of 1% BSA) and incubated on 
plates for 2 hours at 25°C. Plates were washed, then incubated with bioti-
nylated detection antibody followed by streptavidin HRP. Antibody bind-
ing was detected with TMB substrate (KPL), quenched with HCl (1 M), and 
assayed by absorbance at 450 nm. IL-33 level was quantified on a 7-point 
standard curve and normalized to total protein in the sample. For mouse 
samples, lung tissues were homogenized in T-PER reagent (Pierce) with the 
mammalian protease inhibitor cocktail (Sigma-Aldrich), and ELISA was 
performed as described above.
Human lung samples. Clinical samples were obtained from lung explants 
harvested at the time of lung transplantation from COPD recipients (n = 35) 
with very severe disease (GOLD Stage IV) during the period from 2005 to 
2012 at Barnes-Jewish Hospital (St. Louis, Missouri, USA). Control samples 
were obtained from non-COPD donors (n = 18) using both lung explants 
that were otherwise not useable for transplantation and excess lung tissue 
that was resected for downsizing. For the first analysis of gene expression, 
lung explant samples were obtained from a group of COPD recipients 
(n = 7) and non-COPD donors (n = 15) without airway localization. For the 
second analysis of gene expression, samples were obtained from a group of 
COPD recipients (n = 16) and non-COPD donors (n = 7), using CT imaging 
of the lung explant to ensure inclusion of airway tissue, as described previ-
ously (47). Each analysis consisted of samples from COPD recipients with 
the same clinical characteristics (Supplemental Table 2).
Airway epithelial cell culture. Primary culture hTECs were established 
from tracheobronchial specimens of COPD recipients and non-COPD 
donors using 2D submerged and air-liquid interface cultures as well as 
3D sphere culture conditions, as described previously (36, 95). For the 
present experiments, cells were grown in UNC BEGM without retinoic 
acid (RA) or ALI medium (96) in 12-mm Transwell permeable support 
plates (Corning Life Sciences). For 2D cultures, cells in submerged for-
mat were seeded at 20,000 cells/well, grown to confluence (3–5 days) in 
BEGM (upper and lower chambers), and used for study. The air-liquid 
interface condition was established by removing medium from the upper 
chamber and changing the medium in the lower compartment to UNC 
ALI medium supplemented with RA (50 nM), then culturing cells for an 
additional 21 days. For IL-33 release experiments in submerged 2D cul-
tures, cells were incubated with ATP (10 μM) from Cytoskeleton or PBS 
vehicle, and IL-33 level was determined by ELISA and LDH level by activ-
ity assay (Sigma-Aldrich). For 3D tracheobronchosphere cultures estab-
R programming environment (79). Raw bead-level intensity data import 
and background correction was performed using the beadarray package 
(80). Each Mouse-WG6-v2 BeadChip array consists of 2 strips, which must 
be treated separately through bead-type summarization due to potential 
variation in the data from the 2 strips (81). For each strip, low-level analy-
sis and quality control was performed using the beadarray package (82). 
The BASH algorithm was applied to mask beads affected by large spatial 
artifacts (83), followed by bead-type summarization, including outlier 
bead removal (82). Summarized data were log2 transformed, then quan-
tile normalized (84). Bead types whose expression was not detected on any 
strip in the experiment (detection P > 0.05) were removed. Data from the 
2 independently processed strips per array were then merged. Differential 
expression was assessed using linear models and empirical Bayes moder-
ated F statistics, as implemented in the LIMMA package (85). To improve 
interpretation (86), bead types were annotated using annotations from 
Illumina (87), ReMOAT (88), AILUN (89), AceView (90), and Ensembl 
(91). Differences in gene expression were considered significant if P < 0.05 
after adjustment for multiple testing (92), limiting the false discovery rate 
to <5%. Visualization and plotting was performed using DecisionSite for 
Functional Genomics (TIBCO Spotfire). Microarray data were deposited in 
GEO (accession no. GSE49603).
Real-time PCR assay. RNA was purified from lung homogenates using 
TRIzol (Invitrogen) and converted to cDNA using a High-Capacity cDNA 
Archive kit (Applied Biosystems). Target mRNA was quantified by real-
time PCR assay using specific fluorogenic probes and primer sets and the 
Fast Universal PCR Master Mix system (Applied Biosystems). See Supple-
mental Table 3 for primer-probe sets for human and mouse mRNA targets. 
All probes were designed to span introns and did not react with genomic 
DNA. Samples were assayed with the 7300HT or 7500 Fast Real-Time PCR 
System and analyzed using Fast System Software (Applied Biosystems). For 
human tissues, Ct values were normalized to GAPDH mRNA and expressed 
as fold change relative to the mean Ct value for the non-COPD control 
samples using the ΔΔCt method (93). For mice, cDNA mRNA copy num-
bers were corrected for Gapdh mRNA and expressed as fold change relative 
to the mean expression level in control mice.
Immunohistochemistry. Tissues were fixed with 10% formalin, embedded in 
paraffin, cut into 5-μm sections, and adhered to charged slides. Sections 
were deparaffinized in Fisherbrand CitroSolv (Fisher), hydrated, and treat-
ed with heat-activated antigen unmasking solution (Vector Laboratories). 
Immunostaining was performed using primary antibodies (Supplemental 
Table 4) followed by labeled secondary antibodies. Antibody binding was 
detected using diaminobenzidine (DAB) with hematoxylin (in mouse) or 
tartrazine (in human) counterstain for brightfield microscopy, or with 
tyramide-based signal amplification using Alexa Fluor 488 or Alexa Fluor 
594 fluorochromes (Invitrogen) for immunofluorescence microscopy. In 
mouse lung tissue, the number of MUC5AC+ cells was quantified using 
ImageJ software (NIH). In human tissues, the number of IL-33+ cells was 
quantified using Nanozoomer (Hamamatsu) virtual microscopy and Vizio-
morph software (Visiopharm).
FACS analysis. For immune cell experiments, single-cell suspensions were 
generated from minced lung tissue that was subjected to collagenase (Lib-
erase Blendzyme III, Roche), hyaluronidase (Sigma-Aldrich), and DNAse I 
(grade II, Roche) digestion for 45 minutes at 37°C. After FcR blockade, 
lung cell suspensions were incubated with labeled antibodies and sorted 
using a Moflo (DAKO-Cytomation) high-speed cell sorter. Nonviable 
cells were excluded from analysis by 7-AAD staining. Mouse cells were 
immunostained with PE-Cy7–conjugated anti-mouse F4/80 (Ebiosci-
ence) and FITC-Cy5.5–conjugated anti-mouse CD45 (Ebioscience), and 
human cells were immunostained with APC-conjugated anti-human 
CD14 (BD Biosciences) and biotin-conjugated anti-human CD45 (BD 
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lished on pre- and post-sort (IL-33–enriched) populations, cells were 
resuspended in BEGM, mixed 1:1 with growth factor–reduced Matrigel 
(BD Biosciences), and plated at 3 × 103 cells per 100 μl in Transwells. 
After 7 days, medium in lower chamber was changed from BEGM to UNC 
ALI supplemented with RA, and spheres were cultured for 30 days. Dif-
ferentiated spheres were counted and were assessed for ciliary beating 
using the SAVA system. Spheres were harvested from Matrigel using cell 
recovery solution (BD Biosciences) and embedded in OCT (Tissue-Tek) 
for frozen sectioning and immunostaining.
Statistics. Unless otherwise stated, all data are presented as mean ± SEM, 
and 2-tailed unpaired Student’s t test was used to assess statistical signifi-
cance between means. In all cases, a P value less than 0.05 was considered 
significant. All values are representative of at least 3 experiments.
Study approval. All animal experiments were performed using protocols 
approved by the Washington University Animal Studies Committee. All 
human studies were conducted with protocols approved by the Washing-
ton University Institutional Review Board, and subjects provided informed 
consent prior to their participation in the study.
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